Page last updated: 2024-11-10

8-hydroxymanzamine a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

8-hydroxymanzamine A: active against HIV-II; isolated from the sponge Pachypellina; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

8-hydroxymanzamine A : An alkaloid that is manzamine A with a hydroxy substituent at position 8. Isolated from Pachypellina and Acanthostrongylophora, it exhibits inhibitory activity against Glycogen Synthase Kinase-3 (EC 2.7.11.26). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5270765
CHEMBL ID255685
CHEBI ID66669
MeSH IDM0230014

Synonyms (11)

Synonym
8-hydroxymanzamine a
(13s,1r,2r,4r)-25-(8-hydroxybeta-carbolinyl)-11,22-diazapentacyclo[11.11.2.1<2,22>.0<2,12>.0<4,11>]heptacosa-5,16,25-trien-13-ol
(+)8-hydroxymanzamine a
CHEMBL255685
chebi:66669 ,
(4ar,7s,7ar,13z,14ar,15ar,18z)-5-(8-hydroxy-9h-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3h-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1h,7ah)-ol
Q27135288
PD183357
PD183358
(1r,4s,9z,13s,13ar,20ar,21ar)-2,3,5,6,7,8,11,12,15,16,17,18,20a,21-tetradecahydro-24-(8-hydroxy-9h-pyrido[3,4-b]indol-1-yl)-1,13-etheno-4,21a-methano-1h-azocino[1',2':1,5]pyrrolo[3,2-e]azacyclopentadecin-13(13ah)-ol
DTXSID601098210
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
anti-HSV-2 agentAn anti-HSV agent agent that destroys or inhibits the replication of herpes simplex virus-2.
EC 2.7.11.26 (tau-protein kinase) inhibitorAn EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of tau-protein kinase inhibitor (EC 2.7.11.26).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
beta-carbolinesAny pyridoindole containing a beta-carboline skeleton and their hydrogenated derivatives
alkaloidAny of the naturally occurring, basic nitrogen compounds (mostly heterocyclic) occurring mostly in the plant kingdom, but also found in bacteria, fungi, and animals. By extension, certain neutral compounds biogenetically related to basic alkaloids are also classed as alkaloids. Amino acids, peptides, proteins, nucleotides, nucleic acids, amino sugars and antibiotics are not normally regarded as alkaloids. Compounds in which the nitrogen is exocyclic (dopamine, mescaline, serotonin, etc.) are usually classed as amines rather than alkaloids.
isoquinolinesA class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1647728Antiproliferative activity against human CaSki cells assessed as reduction in cell viability at 2 to 4 uM incubated up to 72 hrs by CellTiter-Glo assay
AID1647731Cytotoxicity against human Keratinocytes assessed as reduction in cell viability at 4 uM incubated up to 72 hrs by CellTiter-Glo assay
AID1846861Antimalarial activity against Plasmodium falciparum W22021European journal of medicinal chemistry, Oct-05, Volume: 221Structure activity relationship in β-carboline derived anti-malarial agents.
AID1846859Antimalarial activity against Plasmodium2021European journal of medicinal chemistry, Oct-05, Volume: 221Structure activity relationship in β-carboline derived anti-malarial agents.
AID1846860Antimalarial activity against Plasmodium falciparum D62021European journal of medicinal chemistry, Oct-05, Volume: 221Structure activity relationship in β-carboline derived anti-malarial agents.
AID1666597Induction of DNA damage in human SU8686 cells assessed as increase in gammaH2AX phosphorylation at ser193 at cytotoxic IC50 in presence of 0.3 uM doxorubicin by fluorometry method2020Bioorganic & medicinal chemistry, 02-15, Volume: 28, Issue:4
Targeting the DNA damage response (DDR) by natural compounds.
AID1647727Antiproliferative activity against human SiHa cells assessed as reduction in cell viability at 2 to 4 uM incubated up to 72 hrs by CellTiter-Glo assay
AID1647725Antiproliferative activity against human C33A cells assessed as reduction in cell viability at 2 to 4 uM incubated up to 72 hrs by CellTiter-Glo assay
AID1647726Antiproliferative activity against human HeLa cells assessed as reduction in cell viability at 2 to 4 uM incubated up to 72 hrs by CellTiter-Glo assay
AID1666596Induction of DNA damage in human SU8686 cells assessed as increase in gammaH2AX phosphorylation at ser193 at cytotoxic IC50 in presence of 5 uM cisplatin by fluorometry method2020Bioorganic & medicinal chemistry, 02-15, Volume: 28, Issue:4
Targeting the DNA damage response (DDR) by natural compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (10.00)18.2507
2000's3 (30.00)29.6817
2010's3 (30.00)24.3611
2020's3 (30.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.52 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]